Access to Information Requests Completed – November 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of November 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2009-01417	All documents concerning the classification of biologic drugs as subsequent entry biologic.	Disclosed in part	314
A-2011-00386	All internal and external notes and correspondence in connection with the ad hoc scientific/expert advisory panel that was convened by Health Canada on or about October 26, 2010 regarding caffeinated energy drinks. (Jan 1, 2010 to Jun 30, 2011).	Disclosed in part	457
A-2011-00533	AERs for the product Tylenol. Report numbers: 000314880, 000316264, 000320533, 000321971, 000322261, 000323355, 000327008, 000327009, 000327010 and 000327011.	Disclosed in part	75
A-2011-01133	Information regarding the product Lantus (Insulin Glargine) by Sanofi-Aventis Canada Inc.	Disclosed in part	1,922
A-2011-01156	All documents relating to the use of enzymes in natural health products. (Jan 1, 2008 to Feb 28, 2010).	Disclosed in part	239
A-2011-01471	Memorandum to cabinet, memos, decks, and briefing notes related to the Assisted Human Reproduction Act (C-56 2002, C-13 2003, and C-6 2004).	Disclosed in part	391
A-2011-01492	All documents related to the recommendations for the appointment of the Board of Assisted Human Reproduction Canada.	Disclosed in part	169
A-2011-01576	Briefing notes prepared for the minister. (Jan 1, 2012 to Feb 20, 2012).	Disclosed in part	51
A-2012-00042	Briefing notes prepared for the Minister's office regarding the Marijuana Access program. (Apr 13, 2007 to Apr 12, 2012).	Disclosed in part	24
A-2012-00067	All records related to the Federal/Provincial/Territorial Task Group on Sodium. (Jul 1, 2011 to Aug 31, 2011).	Disclosed in part	161
A-2012-00131	All documents regarding the Federal Tobacco Control Strategy. (Jan 1, 2012 to May 1, 2012).	Disclosed in part	2,112
A-2012-00140	All documents related to approval of Boston Scientific Transvaginal Mesh / Pelvic Support Mesh / Sling. (Jan 1, 1996 to May 3, 2012).	Disclosed in part	419
A-2012-00185	All documents relating to the presentation of studies and/or literature that supported the amendments to Schedule F pertaining to all amendments to the reference to nicotine and its salts for human use, in Part I of Schedule F to the Food and Drug Regulations.	Disclosed in part	245
A-2012-00255	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product INTERCEED Absorbable Adhesion Barrier. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	5
A-2012-00290	Information regarding the product Ongles Et Cheveux, NPN 80028573 by Canafreg Inc.	Disclosed in part	50
A-2012-00315	Information regarding the product Pgx Daily, NPN 80017389 by Natural Factors Nutritional Products Limited.	Disclosed in part	143
A-2012-00316	Information regarding the product Pgx Daily, NPN 80017405 by WN Pharmaceuticals Ltd.	Disclosed in part	121
A-2012-00317	Information regarding the product Pgx Daily, NPN 80021409 by Bioclinic Naturals Inc.	Disclosed in part	43
A-2012-00318	Information regarding the product Pgx Granules, NPN 80021418 by Natural Factors Nutritional Products Limited.	Disclosed in part	68
A-2012-00319	Information regarding the product Pgx Granules; Pgx; Pgx Daily Granules, NPN 80021422 by Bioclinic Naturals Inc.	Disclosed in part	40
A-2012-00321	Information regarding the product Slimstyles Pgx Daily Granules, NPN 80021423 by Natural Factors Nutritional Products Limited.	Disclosed in part	77
A-2012-00322	Information regarding the product Pgx Daily; Pgx Daily Granules, NPN 80021424 by WN Pharmaceuticals Ltd.	Disclosed in part	33
A-2012-00324	Information regarding the product Pgx Granules; Pgx Daily Granules, NPN 80021426 by Bioclinic Naturals Inc.	Disclosed in part	38
A-2012-00325	Information regarding the product Slimstyles Pgx Granules (Natural Orange Flavour), NPN 80021599 by Natural Factors Nutritional Products Limited.	Disclosed in part	43
A-2012-00326	Information regarding the product Pgx; Slimstyles Pgx, NPN 80023705 by Natural Factors Nutritional Products Limited.	Disclosed in part	34
A-2012-00327	Information regarding the product Wellbetx Pgx Ultra Matrix Softgels Plus Mulberry, NPN 80027144 by Natural Factors Nutritional Products Limited.	Disclosed in part	76
A-2012-00328	Information regarding the product Pgx Daily Ultra Matrix Softgels Plus Mulberry, NPN 80027145 by Bioclinic Naturals Inc.	Disclosed in part	47
A-2012-00329	Information regarding the product Pgx(Tm) With Mulberry, NPN 80030853 by Natural Factors Nutritional Products Limited.	Disclosed in part	92
A-2012-00398	Information regarding the natural health product NO Shotgun.	Disclosed in part	268
A-2012-00411	Documents regarding future program plans for anti-smoking/anti-tobacco programs. (Jan 1, 2012 to Jun 13, 2012).	Disclosed in part	1,097
A-2012-00449	Information regarding the product Centrum Advantage, NPN 80013657 by Pfizer Consumer Healthcare.	Disclosed in part	167
A-2012-00463	No Objection Letters or other regulatory opinions issued by Health Canada to Highline Mushrooms regarding the processing of mushrooms and/or the use of ethylenediaminetetraacetic acid (EDTA) with or on mushrooms. (Jan 1, 2000 to Jun 21, 2012).	Disclosed in part	108
A-2012-00515	Information regarding the product Mylan-Telmisartan, DINs 02376717 and 02376725 by Mylan Pharmaceuticals ULC.	Disclosed in part	245
A-2012-00534	AERs for the product Multaq (dronedarone). Report numbers: 000116160, 000128682, 000177462, 000186000, 000210532, 000223075, 000304515, 000349275, 000356458 and 000360386.	Disclosed in part	35
A-2012-00536	Information regarding the product Vitamin B12 1200 Mcg Timed Release, NPN 00480878 by Jamieson Laboratories Ltd.	Disclosed in part	64
A-2012-00562	The complete scientific review and approval documentation for Humatrope in the treatment of Idiopathic Short Stature.	Disclosed in part	20
A-2012-00574	AERs. Report numbers: 000408023, 000403732, 000399863, 000404380, 000404860, 000406208, 000406216, 000406218, 000406219, 000406464, 000412030 and 000412041.	Disclosed in part	56
A-2012-00575	Original application submitted by Portland Hotel Services Society / Vancouver Coastal Health authority for an exemption to Controlled Drugs and Substances Act, for operation of a supervised injection site in Vancouver, known as InSite. (Jan 1, 2001 to Jul 20, 2012).	Disclosed in part	29
A-2012-00606	All comments received pertaining to a notice to add Methylenedioxypyrovalerone "Bath salts" to schedule 1 of the Controlled Drugs and Substances Act.	Disclosed in part	26
A-2012-00629	All documents related to the attendance of Health Canada officials at the Framework Convention on Tobacco Control in Punta del Este, Uruguay in November 2010.	Disclosed in part	242
A-2012-00631	Correspondence or briefing notes provided to Health Canada regarding Articles 17 and 18 of the World Health Organization's Framework Convention on Tobacco. (Nov 1, 2010 to Jul 27, 2012).	Disclosed in part	78
A-2012-00638	AERs for the product Cipralex. Report numbers: 000400698, 000403276, 000409778, 000420206, 000420215, 000422786, 000422989 and 000425373.	Disclosed in part	20
A-2012-00643	AERs for the product Epival. Report numbers: 000377420 and 000378524.	Disclosed in part	11
A-2012-00654	Complete contracts from 2000 thru 2014 regarding consulting, production, distribution, all payment schedules, fees paid by government(s) other company paid directly regarding Marihuana Medical Access Regulations program relating to Prairie Plant Systems Inc.	Disclosed in part	282
A-2012-00655	The contribution agreement and its amendments (as well as the evaluation documents) between Health Canada and the Canadian Partnership Against Cancer.	Disclosed in part	354
A-2012-00672	All documents concerning the Tsuu T'ina First Nations/Redwood Meadows sewage system. (Jun 1, 2012 to Jul 31, 2012).	Disclosed in part	323
A-2012-00677	List of all Question Period notes created for the minister of Health. (Jun 1, 2012 to Jul 31, 2011).	All disclosed	170
A-2012-00692	All documents in the purpose of follow-up for the meeting between the JTI-Macdonald Corp. and Hilary Geller, held on May 18, 2011.	Disclosed in part	31
A-2012-00776	Internal communication about the strategy, rationale, deliberation and/or execution of media publicity that featured people other than Members of Parliament who had a significant public profile in Health Canada's communications. (Jan 1, 2006 to Aug 9, 2012).	No records exist	0
A-2012-00777	Internal communication and files about Health Canada's use of graphic arts visuals that are commonly identified with the Conservative Party of Canada on external communication materials such as advertising, direct marketing, Internet marketing. (Jan 1, 2006 to Aug 9, 2012).	No records exist	0
A-2012-00793	Correspondence between Health Canada and the Canadian delegation attending the Fifth session of the Conference of the Parties (COP5) regional (Americas) meeting held September 17-21, 2012 and the Conference of the Parties to the World Health Organization Framework Convention on Tobacco Control fifth session from November 12-17, 2012.	Disclosed in part	30
A-2012-00796	All documents about the Peg Perego strollers recalled on July 30, 2012. (Mar 1, 2012 to Aug 7, 2012).	Disclosed in part	454
A-2012-00804	Information regarding the product Buckley's Complete Nighttime Softgels, DIN 02335239.	Disclosed in part	30
A-2012-00805	Information regarding the product Buckley's Complete Daytime Plus Mucus Relief Softgels, DIN 02335948.	Disclosed in part	30
A-2012-00813	All documents that relate to the proposal for evaluating the potential health effects of wind turbine noise for projects in reference to the Canadian Environmental Assessment Act J Low Freq Noise V A 2008, 27-253-265.	Disclosed in part	1,316
A-2012-00815	All documents regarding The Science Advisory Board Meeting of February 1-2, 2012 and the agenda items of Health Canada's Policy and Research Approach for Wind Turbines.	Disclosed in part	117
A-2012-00819	All documents between Health Canada and any representative of the World Health Organization relating to sound, noise or wind turbines. (Jan 1, 2007 to Aug 8, 2012).	Disclosed in part	194
A-2012-00835	All communication between Health Canada employees Croplife Canada or Croplife, regarding actual or proposed changes to regulations or laws concerning pesticides. (Jan 1, 2011 to August 22, 2012).	Disclosed in part	1
A-2012-00855	AERs for the product Mirena. Report numbers: 000418735, 000419034 and 000423735.	Disclosed in part	6
A-2012-00864	Copy of the e-mail submission made by the Canadian Federation of Podiatric Medicine dated June 1 2012 in response to prepublication of the proposed New Classes of Practitioners Regulation under the Controlled Drugs and Substances Act.	All disclosed	6
A-2012-00883	All federally-funded research done on cannabis marihuana, medical marijuana.	All disclosed	3
A-2012-00891	All audits of Vision Care Service providers under the Non-Insured Health Benefits Programs. (Jan 1, 2011 to Sep 11, 2012).	Disclosed in part	27
A-2012-00902	All approved Product Monographs for the product Heparin by B. BRAUN MEDICAL INC.	All disclosed	42
A-2012-00907	Line listing for all briefing notes, including memorandums that were created for or sent to the minister. (Jun 1 2012 to Jul 31, 2012).	Disclosed in part	94
A-2012-00917	AER for the product Champix. Report number: 000414847.	Disclosed in part	4
A-2012-00954	Any reports on suicides or suicide attempts that may be related to workforce adjustment during the period between March to August 2012.	No records exist	0
A-2012-00955	List of all Special Examination Reports related to the Non-insured Health Benefits program. (Jan 1, 2009 to Oct 1, 2012).	All disclosed	1
A-2012-00957	All briefing notes related to consumer product based issues including memos created or forwarded to the minister responsible for health between May 1, 2011 and July 1, 2011.	All disclosed	61
A-2012-00963	AERs for the product Diclectin. Report numbers: 000359013, 000359246 and 000417785.	Disclosed in part	22
A-2012-00966	All documents related to Health Canada's policy on wind turbines and/or wind turbine noise and/or wind turbine health effects. (Jan 1, 2004 to Oct 2, 2012).	No records exist	0
A-2012-00968	All documents that relate to the HealthInsider "Traffic Noise Outside the Home" POR 02-65 S conducted in December 2002 by IBM Business Consulting Services. (Jan 1, 2008 to Oct 2, 2012).	Disclosed in part	763
A-2012-00969	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of September 2012.	Disclosed in part	88
A-2012-00975	Periodic safety update reports for Concerta. (Oct 4, 2010 to Oct 3, 2012).	No records exist	0
A-2012-00976	Periodic safety update reports for Adderall XR. (Oct 4, 2010 to Oct 3, 2012).	No records exist	0
A-2012-00977	Periodic safety update reports for Biphentin. (Oct 4, 2010 to Oct 3, 2012).	No records exist	0
A-2012-00979	Periodic safety update reports for Ritalin. (Oct 4, 2010 to Oct 3, 2012).	No records exist	0
A-2012-00980	Periodic safety update reports for Novo-Methylphenidate. (Oct 4, 2010 to Oct 3, 2012).	No records exist	0
A-2012-01000	All contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of September 2012.	Disclosed in part	40
A-2012-01003	All Yearly Status Reports of Guaranteed Loans submitted by the Woodstock First Nation in New Brunswick. (Jan 1, 2005 to Oct 9, 2012).	No records exist	0
A-2012-01006	Audit done by KPMG of Athabasca Health Authority and Vince Robillard (Chief Executive Officer) in 2011 for Saskatchewan Health.	No records exist	0
A-2012-01008	Internal document that states the bibliographies of the journal articles or textbook references Health Canada deems acceptable to show the safety and efficacy of green lipped mussel (Perna canaliculus) or blue mussel in any form (powdered, oil extract, etc.).	No records exist	0
A-2012-01013	Data pertaining to losses and thefts of Dilaudid. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	16
A-2012-01019	Copy of all reports or audits prepared on the Little Saskatchewan First Nation, Manitoba. (Jun 1, 2012 to Oct 12, 2012).	Disclosed in part	78
A-2012-01020	Profile (statistics) of Health Canada employee representation in the groups designated by the Employment Equity Act in the Quebec region (excluding the National Capital region) for 2009 to 2011.	All disclosed	3
A-2012-01025	All responses sent by Health Canada to any comments submitted through the Wind Turbine Stakeholder Comments.	Disclosed in part	23
A-2012-01026	All documents that relate to Noise Propriety Questions developed for Health Canada, Health Canada Insider No. 7, developed by Price Waterhouse Consulting. (Jan 1, 2008 to Oct 12, 2012).	Disclosed in part	338
A-2012-01030	Data pertaining to losses and thefts of Oxycontin. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	59
A-2012-01031	Data pertaining to losses and thefts of Hydromorph Contin. (Jan 1, 2011 to Dec 31, 2011).	All disclosed	28
A-2012-01032	Data pertaining to losses and thefts of Oxycontin. (Jun 1, 2012 to Aug 31, 2011).	All disclosed	4
A-2012-01033	Data pertaining to losses and thefts of OxyNeo. (Jun 1, 2012 to Aug 31, 2011).	All disclosed	4
A-2012-01034	Data pertaining to losses and thefts of Hydromorph Contin. (Jun 1, 2012 to Aug 31, 2011).	All disclosed	5
A-2012-01035	Data pertaining to losses and thefts of Dilaudid. (Jun 1, 2012 to Aug 31, 2011).	All disclosed	2
A-2012-01044	All documents regarding Food Mail meeting between the Minister and officials of NorTerra Inc. held on November 18, 2009.	Disclosed in part	5
A-2012-01048	The minutes, financial statements and supporting documents for meetings between Health Canada and the Mushuau Innu First Nation on August 22, 2012 (in Natuashish) and August 29, 2012 (in St John's).	No records exist	0
A-2012-01056	The total amount of money spent yearly by Health Canada to maintain all hospital care settings. (Sep 1, 2001 to Sep 30, 2012).	No records exist	0
A-2012-01059	Copy of the document entitled "Assessment Report of the Canadian Food Inspection Agency Activities Related to the Safety of Imported Fresh Fruits and Vegetables."	No records exist	0
A-2012-01071	Names of all people who participated in the verbal conversation that led to the deletion of the sentence "Certain members of the general public may be more susceptible to harm from microwave exposure" in the 2009 Safety Code 6.	No records exist	0
A-2012-01084	All documents regarding e coli 0157 and The Congo, and or XL Foods and hand sanitation. (Aug 1, 2012 to Oct 26, 2012).	No records exist	0
A-2012-01094	AERs. Report numbers: 000379425, 000435116 and 000444043.	Disclosed in part	3
A-2012-01096	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of October 2012.	Disclosed in part	68
A-2012-01097	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during October 2012.	All disclosed	2